Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: The Heart and Estrogen/Progestin Replacement Study (HERS)

JAMA

Volumn 277, Issue 16, 1997, Pages 1281-1286

  Schrott, Helmut G ^a,e   Bittner, Vera ^b   Vittinghoff, Eric ^c   Herrington, David M ^d   Hulley, Stephen ^c  

^a UNIVERSITY OF IOWA   (United States)

^b Center for Palliative Care   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL;

ADULT; AGE; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; EDUCATION PROGRAM; FEMALE; HEALTH SERVICE; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT PLANNING;

EID: 0030945970     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.16.1281     Document Type: Article

References (34)

1. Eaker ED, Packard B, Thom TJ. Epidemiology and risk factors for coronary heart disease in women. Cardiovasc Clin. 1989;19:129-145.
2. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111:383-390.
3. Dittrich H, Gilpin E, Nicod P. Acute myocardial infarction in women: influence of gender on mortality and prognostic variables. Am J Cardiol. 1988;62:1-7.
4. Greenland P, Reicher-Reiss H, Goldlourt U. In-hospital and 2-year mortality in 1,524 women after myocardial infarction: comparison with 4,315 men. Circulation. 1991;83:484-491.
5. Khan SS, Nessim S, Gray R. Increased mortality of women in coronary artery bypass surgery: evidence for referral bias. Ann Intern Med. 1990;112: 561-567.
6. Cowley MJ, Mullin SM, Kelsey SF. Sex differences in early and long-term results of coronary angioplasty in the NHLBI PTCA Registry. Circulation. 1985;71:90-97.
7. Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M. Cardiovascular disease in women: AHA Medical/Scientific Statement. Circulation. 1993;88:1999-2009.
8. Davis KB, Chaitman B, Ryan T, Bittner V, Kennedy JW. Comparison of 15 year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS Registry study. J Am Coll Cardiol. 1995;25:1000-1009.
9. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148: 36-69.
10. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Hauel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
11. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
12. The Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993; 269:3015-3023.
13. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
14. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
15. Lewis SJ, Mitchell JS, East C, et al. Women in CARE have earlier and greater response to pravastatin post myocardial infarction. Circulation. 1996; 94(suppl):I-12. Abstract.
16. Miettinen TA, Pedersen T, Pyorala K, Kjekshus TK. Cholesterol lowering with Simvastatin reduced major coronary events, revascularization procedures and cardiovascular hospitalizations in women participating in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1996;94 (suppl):I-12, Abstract.
17. Werbel BL, Herrington DM, Brubaker PH, et al. Impact of the new National Cholesterol Education Program (NCEP) guidelines on management of cardiac rehabilitation patients. J Cardiac Rehabil. 1994;14:320. Abstract.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18: 499-502.
19. +2 with HC03. Clin Chem. 1984;30:839-842.
20. Myers GL, Cooper GR, Winn CL, et al. The Center for Disease Control-National Heart Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105-135.
21. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons Inc; 1989.
22. Statistical Analysis System, Versian 6.11.Cary, NC: SAS Institute Inc; 1995.
23. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100:605-610.
24. Garber AJ. Chronic, persistent hyperglycemia: an essential flow in diabetes management in America. Clin Diabet. 1996;14:2-9.
25. Hall WD, Kong W. Hypertension in blacks: non-pharmacologic and pharmacologic therapy. In: Saunders E, ed. Cardiovascular Diseases in Blacks. Philadelphia, Pa: FA Davis Co; 1991:157-169.
26. Rich MW, Bosner MS, Chung MK, Shen J. Is age an independent predictor of early and late mortality in patients with acute myocardial infarction? Am J Med. 1992;92:7-13.
27. Manolio TA, Furberg CD. Age as a predictor of outcome: what role does it play? Am J Med. 1992; 92:1-6.
28. Schrott HG, LeGault C, Stefanick ML, et al. Lipids in postmenopausal women: baseline findings of the Postmenopausal Estrogen/Progestin Interventions trial. J Wom Health. 1994;3:155-164.
29. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
30. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 1990;264: 3013-3017.
31. Schrott HG, Stein EA, Dujovne CA, et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995;75:34-39.
32. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by arvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-682.
33. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208. Correction: JAMA. 1995;274:1676.
34. BabirakSP, Mann CA, Anderson GP, Cacchrone JG, Flocke SA, Zyzanske SJ. Outcomes from a lipid clinic. Circulation. 1996;94(suppl):I-50. Abstract.